AtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lifted its position in AtriCure, Inc. (NASDAQ:ATRC) by 165.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,540 shares of the medical device company’s stock after acquiring an additional 77,055 shares during the period. Knights of Columbus Asset Advisors LLC owned 0.26% of AtriCure worth $4,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Snowden Capital Advisors LLC increased its position in shares of AtriCure by 3.5% in the 1st quarter. Snowden Capital Advisors LLC now owns 7,400 shares of the medical device company’s stock valued at $307,000 after acquiring an additional 250 shares during the period. State of Wyoming increased its position in shares of AtriCure by 34.6% in the 2nd quarter. State of Wyoming now owns 1,030 shares of the medical device company’s stock valued at $51,000 after acquiring an additional 265 shares during the period. PNC Financial Services Group Inc. increased its position in shares of AtriCure by 4.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 6,791 shares of the medical device company’s stock valued at $335,000 after acquiring an additional 286 shares during the period. Rockefeller Capital Management L.P. increased its position in shares of AtriCure by 15.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,444 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 319 shares during the period. Finally, Mariner LLC increased its position in shares of AtriCure by 6.3% in the 4th quarter. Mariner LLC now owns 5,715 shares of the medical device company’s stock valued at $254,000 after acquiring an additional 337 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on ATRC. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of AtriCure in a report on Wednesday, April 10th. StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. UBS Group increased their target price on shares of AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, Stifel Nicolaus lowered their target price on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.57.

AtriCure Stock Performance

ATRC opened at $23.20 on Friday. AtriCure, Inc. has a twelve month low of $22.42 and a twelve month high of $59.61. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.66 and a current ratio of 3.57. The company has a 50-day moving average price of $30.83 and a 200 day moving average price of $34.28.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, February 15th. The medical device company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. During the same quarter in the prior year, the firm earned ($0.09) EPS. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. Equities research analysts predict that AtriCure, Inc. will post -0.71 EPS for the current year.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Karl S. Dahlquist sold 8,231 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total value of $307,510.16. Following the completion of the sale, the insider now owns 52,839 shares in the company, valued at approximately $1,974,065.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the sale, the insider now owns 74,284 shares in the company, valued at approximately $2,727,708.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Karl S. Dahlquist sold 8,231 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $37.36, for a total transaction of $307,510.16. Following the sale, the insider now owns 52,839 shares of the company’s stock, valued at approximately $1,974,065.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,116 shares of company stock worth $468,797. Insiders own 3.20% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.